Patterns of C-reactive protein (CRP) release were derived from frequent CRP measurements in a cohort of 66 consecutive patients receiving allogeneic bone marrow transplants (BMT) in our unit. Based on a retrospective study of clinical events occurring within the first 40 days after BMT, patients with major transplant-related complications (MTC+ group, n = 22) could be separated from those with fever or mild complications only (MTC− group, n = 44). Treatment-related mortality in the MTC+ group was significantly higher: 32 vs 0% (P Ͻ 0.001). Major complications included veno-occlusive liver disease (VOD), severe endothelial leakage syndrome (ELS), pneumonitis and acute GVHD ϾII. The severity of complications was reflected by the patterns of CRP release with continuously high levels preceding the maximal signs and symptoms of MTC. Univariate analysis showed that, among other variables (sex, age, disease status at transplant, ؎TBI in the conditioning regimen, ؎ use of myeloid growth factors after BMT, time to reach PN Ͼ200/mm 3 ), three factors were significantly associated with MTC: maximal levels of CRP during the post-transplant episode (CRPmax) (296.6 ؎ 91.8 vs 88.9 ؎ 55.8 mg/100 ml, P Ͻ 0.001), the use of unmanipulated graft (no T depletion) (46.9 vs 12.5%, P Ͻ 0.009) and the CRP level on the day of BMT (CRPo) (42.7 ؎ 55.4 vs 18.2 ؎ 19.5, P = 0.045). In multivariate analysis, using a stepwise logistic regression model including the same variables, CRPmax appeared to be the strongest independent variable (P Ͻ 0.001) and a reliable (94% accuracy) parameter to assess the risk of MTC. Based on this model, CRP levels of 200 and 300 mg/100 ml are associated with a risk of 48 and 94% of developing MTC, respectively. We conclude that CRP monitoring after BMT identifies patients at risk of severe transplant-related complications and mortality. Keywords: CRP levels; severe complications; transplantrelated mortality; allogeneic BMT Correspondence: Dr R Schots, Dienst Medische Oncologie en Hematologie, Laarbeeklaan 101, 1090 Brussels, Belgium Received 6 November 1997; accepted 14 February 1998 Despite substantial improvement in supportive care after allogeneic bone marrow transplantation (BMT), early treatment-related complications still account for a 10-20% mortality in cases of HLA-compatible sibling and up to 40-50% in cases of volunteer unrelated donor (VUD) BMT.
Despite substantial improvement in supportive care after allogeneic bone marrow transplantation (BMT), early treatment-related complications still account for a 10-20% mortality in cases of HLA-compatible sibling and up to 40-50% in cases of volunteer unrelated donor (VUD) BMT. 1, 2 Severe complications during the early post-transplant episode include infections, acute graft-versus-host disease (AGVHD), veno-occlusive liver disease (VOD), endothelial leakage syndrome (ELS) and pneumonitis. 3 C-reactive protein (CRP) is an acute phase protein produced by the liver in several inflammatory states. 4 In marrow transplant recipients, CRP levels have been reported to increase in association with bacterial infections and to a lesser extent with aGVHD. 5 The value of CRP monitoring after BMT is unclear. Therefore, we performed a retrospective analysis in a large number of BMT patients consecutively transplanted in our unit. CRP was monitored frequently in all patients throughout the early post-transplant episode. We found that the magnitude of CRP release was closely related to the severity of complications and the occurrence of treatment-related mortality.
Patients and methods

Patients
A total of 66 patients consecutively transplanted in our unit were analysed. There were 44 male and 22 female patients and median age was 38 years (range . Disease status at time of transplant was: CML (first chronic phase: n = 25, accelerated phase or blast crisis: n = 3), AML in first or second remission (n = 14), ALL in first or second remission (n = 6), myelodysplastic syndrome (n = 6), severe aplastic anemia (n = 5), multiple myeloma (n = 4), lymphoma (n = 3). The conditioning regimens included total body irradiation (TBI, 2 × 5 Gys) in the majority of patients: cytosine arabinoside 4 g/m 2 + cyclophosphamide 120 mg/ kg + TBI (n = 47), cyclophosphamide 120 mg/kg + TBI (n = 5), etoposide 700 mg/m 2 + cyclophosphamide 120 mg/ kg + TBI (n = 3) and cyclophosphamide 80 mg/kg + melphalan 100 mg/m 2 + TBI (n = 1). Regimens without TBI were: cyclophosphamide 200 mg/kg (n = 4), cyclophosphamide 200 mg/kg + ATG (90 mg/kg) (n = 1), busulfan (16 mg/kg) + cyclophosphamide 120-200 mg/kg (n = 3) and thiotepa 750 mg/m 2 + busulfan 12 mg/kg + cyclophosphamide 120 mg/kg (n = 2). Marrows were derived from HLA-compatible siblings (n = 56) or volunteer unrelated donors (n = 10) and were partially depleted of T cells (E-rosetting) in 33 cases. Of the 10 VUD-derived marrows, nine were T cell depleted. Other GVH prevention consisted of cyclosporin A with short course methotrexate in general and cyclosporin monotherapy in cases of T cell depletion. All patients received standard supportive care including isolation in laminar flow rooms, empirical broadspectrum antibiotherapy in case of fever, low dose heparin (100 U/kg daily) as VOD prevention, high-dose immunoglobulins and aciclovir (3 × 250-500 mg/m 2 ) as herpes simplex/CMV prophylaxis. Platelet transfusions (single donor only) were given when the platelet count decreased to less than 20 × 10 9 /l. In a minority of cases, G-CSF (n = 11) or GM-CSF (n = 1) were used from the day of transplant until neutrophil recovery.
Clinical events
A retrospective analysis of the patient's records included the first 40 days after transplant, corresponding to the neutropenic episode and shortly thereafter until recovery from complications or hospital discharge. All episodes of fever and the accompanying clinical events were carefully recorded. Fever was defined as body temperature of Ͼ38°C and Ͻ38.5°C measured on two occasions with at least 4 h interval or one measurement of у38.5°C, without concomitant transfusion of packed cells or platelets. Patients who had fever without complications were classified as 'fever only'. Bacteremia was defined as the finding of at least two positive cultures obtained from separate blood samples drawn during the same episode of fever. VOD was diagnosed according to the clinical criteria as described earlier, including the presence of at least two of the following features: jaundice, hepatomegaly and right upper quadrant pain, ascites and/or unexplained weight gain. 6 ELS was defined as the occurrence of fluid retention and weight gain of Ͼ3%, in the absence of cardiac failure and with insufficient response to diuretics, requiring fluid restriction, albumin administration and dopamine therapy. The weight as well as fluid balance were monitored daily in every patient. The baseline for the 3% weight gain that we systematically used in this study was the weight noted in the patient, 1 or 2 days before the progressive weight gain which is characteristic of the syndrome. In the presence of fluid retention (defined as Ͼ1000 ml positive balance over 24 h), a standardized sequence of measures was adapted in all patients. As a first step, fluid imput was restricted as was felt necessary and i.v. furosemide (repeated doses of 20-40 mg) was started. Human albumins were generally administered whenever the albumin level decreased to below 3 g/100 ml. Insufficient response to furosemide was defined as a continuous weight gain and persistence of oliguria and signs of fluid retention. If signs persisted, dopamine was started in a second step at a dose of 3 g/kg/min. If, despite these measures, the patient's weight increased to Ͼ3% above baseline, he/she was diagnosed as having severe ELS. In general, ELS could easily be distinguished from cardiac failure. All patients with ELS had fever and did not present with typical signs of cardiac failure (dyspnea/orthopnea, Xray findings). We did not perform intracardiac pressure monitoring but, in doubtful cases, we had the patient examined by echocardiography to evaluate left ventricular contractility and ejection fraction. The diagnosis of pneumonitis was only made in cases of fever and respiratory symptoms such as cough and dyspnea that could not be related to cardiac failure or generalized fluid retention and with clear demonstration of pulmonary infiltrates on chest X-ray. aGVHD was diagnosed and staged as earlier described. 7 
CRP measurement
Serum levels of CRP were measured by nephelometry (Behring, Marburg, Germany; normal: Ͻ0.3 mg/dl). Samples were taken on day 0 or day 1 after BMT (baseline levels) and then every 24 or 48 h until death or at least 3 weeks after BMT.
Results
Clinical events
All patients developed fever and in 30% no infection or other precipitating condition could be identified. These cases were classified as 'fever only'. In the majority of patients (70%) some infection or other early transplantrelated complication was documented (Table 1) . Bacteremia was observed in 47 and in 29% of these cases caused by streptococcus species. Only severe cases of stomatitis, corresponding to Ͼgrade 2 according to the NCIC extended toxicity criteria 8 were considered, occurring during 23% of transplant episodes. In 21% of patients, there was clear evidence of unexplained fluid retention (Ͼ1000 ml of positive fluid balance in 24 h) but they did not reach the Ͼ3% weight gain necessary to be qualified as ELS. These cases were classified as 'moderate ELS'. aGVHD was seen in 18% and staged as severe (ϾII) in half of the cases. VOD Table 1 Clinical events observed according to type of transplant In case of sibling transplants (SIB), there was significantly (*) more bacteremia (P = 0.007), stomatitis grade Ͼ2 (P = 0.027) and ELS (P = 0.009) when unmanipulated (no T depletion) marrows were used (Fisher's exact test).
occurred in 17% and pneumonitis in 9% of patients. There was no patient presenting with fever and pulmonary infiltrates who qualified as suffering from cardiac failure. Only two patients had ELS with maximal symptoms that preceded subsequent pneumonitis by several days and so they were considered as having two consecutive MTCs. Some patients with severe ELS had pulmonary rales detected by physical examination but no clear infiltrate on X-ray; they were not considered as having pneumonitis. In all cases of pneumonitis, bronchoscopy and broncho-alveolar lavages were done and bacteriological examination was positive on only one occasion (aspergillosis). Early (Ͻ40 days) treatment-related mortality occurred in 11% of patients and was primarily due to VOD (n = 3), ELS followed by aGVHD II-III and cerebral aspergillosis (n = 1), VOD evolving into hepato-renal failure (n = 1), ELS followed by streptococcal sepsis (n = 1) and pneumonitis (n = 1). As shown in Table 1 , bacteremia, severe stomatitis and ELS were seen more frequently after BMT using unmanipulated marrows (not T cell depleted).
Based on previously used definitions, 3 we further categorized the observed transplant-related complications into relatively mild (uncomplicated bacteremia, stomatitis, moderate ELS, aGVHD I-II) and severe (VOD, severe ELS, pneumonitis or aGVHD ϾII). Of the 22 patients developing at least one severe complication, seven (32%) had a fatal outcome. Furthermore, death was always preceded by or directly related to one or more severe complications. In contrast, none of the 44 patients having only mild complications died. This difference in mortality between patients with and without MTC was highly (P Ͻ 0.001) significant (Fisher's exact test). All 66 patients could thus be assigned to one of four subgroups: fever only (n = 20), mild complications only (n = 24), severe complications (n = 15) and severe complications followed by death (n = 7) or, alternatively, into two major clinical categories: with (n = 22) or without (n = 44) the occurrence of major (severe complication Ϯ death) transplant-related complications (MTC).
CRP: maximal levels
CRP was monitored for a median duration of 23 days (range: 5-40). Maximal CRP levels (CRPmax) were related to the severity of the complications (Table 2) . No patient with CRPmax levels remaining below 100 mg/100 ml Table 2 Patients according to category of complication and CRPmax (mg/100 ml) developed severe complications and no patient with levels below 200 mg/100 ml died. CRPmax levels above 200 mg/ml were seen in 80% of patients with severe complications and mortality was 31% in cases where levels above 300 mg/100 ml were seen. Significant differences in CRPmax were noted between clinical subgroups 'mild only' vs 'fever only' (P = 0.036), 'severe' vs 'mild only' (P Ͻ 0.001) (Scheffe's procedure for multiple comparison) and MTC+ vs MTC− (P Ͻ 0.001) (Student's t-test) (Figure 1) .
CRP: patterns
The CRP patterns observed were typically monophasic (increasing from baseline over several days to a maximal level followed by gradual decline or remaining high if followed by death of the patient) or biphasic (two peak levels observed in cases of complications occurring consecutively) ( Figure 2 ). Patterns were qualified as mon- CRP (mg/100 ml) CRP (mg/100 ml) CRP (mg/100 ml) CRP (mg/100 ml) CRP (mg/100 ml) CRP (mg/100 ml) ophasic in 46 and biphasic in 20 cases. Maximal CRP levels were consistently observed to closely precede or coincide with maximal clinical signs and symptoms. The patterns of CRP reflected the clinical outcome of a particular complication: in cases of continuous rise of CRP to high levels, with no or little decrease despite therapeutic measures, the patient was likely to develop MTC. To clarify the timing of the rise of CRP relative to the MTC, we defined objective definitions for the maximal signs of the MTC as follows: the day on which maximal weight gain (%) was reached for ELS, maximal bilirubin value for VOD, appearance of infiltrates on X-ray for pneumonitis, day of start of steroid therapy for aGVHD and day of death. As reference value for CRP we used 200 mg/100 ml since, as stated above, levels above this value were associated with MTC and toxic death. A total of 30 non-fatal MTC occurred in 15 patients (Table 2 ) and in 27 of these a CRP value of at least 200 mg/100 ml was reached. In two cases, this value was reached a few days after maximal signs, in five it coincided and in 20 cases (74%) it preceded the maximal signs at a median of 4.5 days (range 1-26). In the seven cases with fatal outcome, the value of 200 mg/100 ml was reached at a median of 5 days (range 2-23) before death. From these data, it appears that in all patients developing MTC, CRP starts to rise before the signs and symptoms become prominent and that, in the majority of cases, high levels of CRP are noted days or even weeks before maximal symptoms of MTC can be recognized.
There was a clear relationship between the duration of CRP release and severity of clinical events: the median number of days with levels above 100 mg/100 ml was 2 days in patients developing minor complications and 8.5 days in the 'major non-fatal group' (P Ͻ 0.001) (MannWhitney). Analysing all 27 evaluable patients with a CRPmax of at least 100 mg/100 ml, the correlation (Spearman rank) between CRPmax and duration of CRP release was highly significant (r = 0.7, P Ͻ 0.001).
Analysis of risk factors
Together with CRPmax, several factors, likely to have some influence on early outcome after BMT, were tested for whether or not they increased the risk of developing MTC: sex, age, disease status at time of BMT, TBI, T cell depletion of the graft, use of myeloid growth factors after transplant, time to reach 200 PN/mm 3 and CRP levels on the day of transplant (CRPo). The results of an univariate analysis using the appropriate statistical tests are shown in Table 3 . Next to CRPmax, only the use of an unmanipulated marrow (no T cell depletion) (46.9 vs 12.5%, P = 0.009) and CRPo (42.7 Ϯ 55.4 vs 18.2 Ϯ 19.5 mg/100 ml, P = 0.045) were significantly related to the occurrence of MTC.
We also performed a multivariate analysis with the same factors using stepwise logistic regression. CRPmax was identified as the strongest independent variable (P Ͻ 0.001) and appeared to be a reliable (94% accuracy) parameter in a model to assess the risk for a particular patient developing MTC, assuming that, at time of measurement her/his maximal CRP level is reached (Figure 3) . Table 3 Univariate analysis of factors that may increase the risk of major complications 
Risk
Discussion
This study includes a representative cohort of essentially adult patients who were consecutively allografted in a single transplant unit. The incidence and the nature of the transplant-related complications that we observed during the first 40 days after BMT correspond to what can be expected from the literature. 1 Using clear definitions for clinical events, we could discriminate severe from relatively mild complications. The validity of this classification is shown by the fact that only patients developing severe complications (VOD, severe ELS, aGVHD ϾII, pneumonitis) were at risk (32%) of early death after BMT. We further used this classification to separate all patients into two distinct clinical categories: those developing severe (fatal or non-fatal) complications (MTC+) and the others (MTC−). Based on frequent CRP measurements, we demonstrated a close relationship between the severity of complications and the magnitude of CRP release (maximal levels and duration). From all 66 patients analysed, 33% developed MTC and CRPmax levels were clearly higher in this group as compared to patients having fever or mild complications only. Even in patients with only minor complications as compared to those with 'fever only', higher CRP levels were noted. It can thus be concluded that, in the early post-transplant setting, the severity of a particular transplant-related complication is closely reflected by the CRP levels. Our results are more informative as compared with the existing literature on CRP levels after BMT. In a series of 68 patients, high levels of CRP were mostly found to be associated with bacterial infections and to a lesser extend with fungal and viral infections or aGVHD. 9 This was confirmed in a series of pediatric patients where high levels of CRP correlated with bacterial infections 10 and in other, smaller series where no increase of CRP was found in aGVHD. [11] [12] [13] [14] Finally, some other studies have shown a relationship between CRP increase and oral mucositis after BMT. 15, 16 CRP is a well-known marker of inflammation 4 which is induced in liver cells mainly by IL-6.
17 IL-6 is produced by many cell types such as monocytes, macrophages, fibroblasts and endothelial cells 18 which may survive the conditioning regimen and respond to tissue damage caused by high-dose cytotoxic agents and infections. Our results suggest that not only the severity and multiplicity of precipitating causes, but also the individual patient's inflammatory response determines outcome in the first weeks after BMT.
As we investigated the possible impact of a number of variables on the early outcome after BMT in an univariate analysis, including patient characteristics (sex, age, disease status at BMT), type of conditioning regimen (Ϯ TBI), type of transplant (Ϯ T depletion), supportive care measurements (Ϯ myeloid growth factors), hematopoietic recovery (time to 200 PN/mm 3 ) and CRP levels, only three factors were significantly associated with MTC: CRPmax, the use of an unmanipulated graft (no T depletion) and CRP levels on the day of transplant (CRPo). T cell depletion of the graft is well-known as the most efficient method to substantially decrease the risk of aGVHD. Our findings also indicate that other severe complications, mostly endothelial damage syndromes such as ELS, also seem to occur less frequently after T cell depletion. This can be explained by the important role of T cells in the inflammatory response through their direct or indirect induction of cytokines, such as IL-6 and TNF␣ that can recruit or enhance tissue damaging processes. 18, 19 In addition, CRP may have some intrinsic, T cell-dependent pathogenic effects, since complement activation by T lymphocytes can be amplified by CRP and lead to endothelial damage. 20, 21 The finding that CRPo is a risk factor is not very surprising as it somewhat reflects the patient's inflammatory response to the conditioning regimen, which may trigger tissue damaging processes leading to MTC during the aplastic phase subsequently.
Finally, CRPmax and all variables that were studied in univariate analysis were also tested in a multivariate analysis using a stepwise logistic regression model. Again, CRPmax appeared to be the strongest independent variable related to the occurrence of MTC. Using this model, it can be calculated that if in a patient, at a certain time after BMT, CRP levels of 200 or 300 mg/100 ml are noted, he/she has a risk of 48 and 94% of developing one or more severe complications, respectively, which, in our hands, holds a 32% risk of mortality. We noted that CRP levels increased several days or even weeks before the maximal signs and symptoms of MTC appeared, an observation which is similar to the one made by Höller et al 3 with regard to levels of TNF␣ after BMT. Therefore, our study shows that high levels of CRP after alloBMT combined with a pattern showing increasing or persistently high levels despite therapeutic measures, predict the occurrence of MTC and eventually treatment-related death.
We conclude that monitoring of CRP after BMT allows identification of patients at risk of early treatment-related complications and mortality. Based on these findings, clinical trials could be designed that aim to reduce early transplant-related mortality by reducing severe inflammatory reactions, for instance, by means of protective cytokines or monoclonal anti-cytokine antibodies.
